Claims
- 1. A method for treating a subject afflicted with intestinal malabsorption, said method comprising:administering to the subject an amount of a composition effective to increase the subject's blood folate level to a normal blood folate level, wherein the composition comprises: one or more natural isomers of reduced folate selected from the group consisting of (6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid, and polyglutamyl derivatives thereof; and a nutritional substance selected from the group consisting of a food preparation, an essential nutrient preparation, and combinations thereof; wherein, when the nutritional substance is a food preparation, the food preparation comprises two or more food components and each gram of said food preparation has a natural molar amount, N, of said one or more natural isomers of reduced folate, wherein N is greater or equal to zero and wherein each gram of said composition has a total molar amount, T, of said one or more natural isomers of reduced folate greater than N; wherein, when the nutritional substance is an essential nutrient preparation, the essential nutrient preparation comprises a vitamin other than ascorbic acid.
- 2. A method according to claim 1, wherein, when the nutritional substance is an essential nutrient preparation and when the composition comprises an amount of 5-formyl-(6S)-tetrahydrofolic acid, the composition further comprises no 5-formyl-(6R)-tetrahydrofolic acid, or, if present, the composition further comprises 5-formyl-(6R)-tetrahydrofolic acid in an amount less than the amount of 5-formyl-(6S)-tetrahydrofolic acid present in the composition.
- 3. A method according to claim 1, wherein the essential nutrient preparation further comprises ascorbic acid.
- 4. A method according to claim 1, wherein the one or more natural isomers of reduced folate is selected from the group consisting of 5-methyl-(6S)-tetrahydrofolic acid, 5-formyl-(6S)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, and polyglutamyl derivatives thereof.
- 5. A method according to claim 1, wherein each of the one or more natural isomers of reduced folate is substantially chirally pure.
- 6. A method according to claim 1, wherein the one or more natural isomers of reduced folate is 5-methyl-(6S)-tetrahydrofolic acid or a polyglutamyl derivative thereof.
- 7. A method according to claim 1, wherein the one or more natural isomers of reduced folate is 5-formyl-(6S)-tetrahydrofolic acid or a polyglutamyl derivative thereof.
- 8. A method according to claim 1, wherein the subject is a human subject.
- 9. A method according to claim 1, wherein the subject is afflicted with celiac disease.
- 10. A method according to claim 1, wherein the subject is afflicted with tropical sprue.
- 11. A method according to claim 1, wherein said administering is carried out periodically.
- 12. A method according to claim 1, wherein said administering is carried out daily.
- 13. A method according to claim 1, further comprising:determining blood folate levels in the subject's blood.
- 14. A method according to claim 1, wherein the one or more natural isomers of reduced folate is 5-methyl-(6S)-tetrahydrofolic acid or a polyglutamyl derivative thereof; wherein the composition further comprises 5-methyl-(6R)-tetrahydrofolic acid or a polyglutamyl derivative thereof; and wherein the 5-methyl-(6S)-tetrahydrofolic acid or polyglutamyl derivative thereof and the 5-methyl-(6R)-tetrahydrofolic acid or polyglutamyl derivative thereof are present in equal molar amounts.
Parent Case Info
The present application is a continuation of U.S. patent application Ser. No. 09/418,649, filed Oct. 15, 1999, now U.S. Pat. No. 6,254,904, which is a continuation of U.S. patent application Ser. No. 09/117,586, filed Jul. 31, 1998, now U.S. Pat. No. 5,997,915, which is a 371 of PCT/US97/01870, filed Jan. 31, 1997, which claims the benefit of U.S. Provisional Patent Application Ser. No. 60/010,898, filed Jan. 31, 1996.
US Referenced Citations (15)
Foreign Referenced Citations (8)
Number |
Date |
Country |
0 382 019 |
Aug 1990 |
EP |
0 388 827 |
Sep 1990 |
EP |
0 482 493 |
Apr 1992 |
EP |
0 595 005 |
May 1994 |
EP |
0 646 322 |
Apr 1995 |
EP |
407147911 |
Jun 1995 |
JP |
407291864 |
Nov 1995 |
JP |
408070788 |
Mar 1996 |
JP |
Non-Patent Literature Citations (9)
Entry |
Brown, J.P. et al., Gastroenterology 64(2):223-232 (1973). |
Colman, N. et al., Am J Clin Nutr 28:459-464 (1975). |
Gregory, J.F. et al., Am J Clin Nutr 55:1147-1153 (1992). |
O'Broin, J.D. et al., Am J Clin Nutr 28:438-444 (1975). |
Perry, J. and Chanarin, I., Br J Haemo 18:329-339 (1970). |
Tamura, T. and Stokstad, E.L.R., Br J Haemo 25:513-532 (1973). |
IMS World database accession No. 94:61435 Druglaunch (1994). |
Poncz et al., Journal of Pediatrics, 98:76-69 (1981). |
Poncz et al., The Journal of Pediatries, 120:948 (1996). |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/010898 |
Jan 1996 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09/418649 |
Oct 1999 |
US |
Child |
09/888798 |
|
US |
Parent |
09/117586 |
|
US |
Child |
09/418649 |
|
US |